Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Booster immunogenicity study of different COVID-19 vaccines in healthy adults
ChiCTR2200057278Phase 4Recruiting
- Sponsor
- Health Service Department of the Central Guard Bureau
- Start
- Dec 2021
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of ad5-ncov, ZF2001 and turkovac in coronavirus disease 2019 (COVID-19) (5 arms), sponsored by Health Service Department of the Central Guard Bureau. Primary endpoints: Neutralizing antibodies against SARS-CoV-2 at Day 14 after booster dose and Binding antibodies against SARS-CoV-2 spike at Day 14 after booster dose. Started Dec 2021; status: recruiting.
02
Drugs
ad5-ncovZF2001turkovac
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2200057278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057278.